First-in-human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC-2394, in healthy volunteers
Tang, Fei, Kunder, Rebecca, Chu, Tom, Hains, Avis, Nguyen, Allen, McBride, Jacqueline M, Zhong, Yu, Santagostino, Sara, Wilson, Maria, Trenchak, Abigail, Chen, Liuxi, Ly, Justin, Moein, Anita, Lewin-Koh, Nicholas, Raghavan, Vibha, Osaghae, Uyi, Wynne, Chris, Owen, Ryan, Place, David
Published in Clinical and translational science (01.09.2023)
Published in Clinical and translational science (01.09.2023)
Get full text
Journal Article